ArticleJournal of rare diseases research & treatment2017
The accuracy of hospital ICD-9-CM codes for determining Sickle Cell Disease genotype.
Article in Journal of rare diseases research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 39 citations in OpenAlex.
- Classifying Sickle Cell Disease Subtypes from Clinical Reports: Algorithm Validation and ICD-10 Accuracy Assessment in Five French Hospitals.Journal of medical systems · 2026Article
- Patterns of hormonal contraception use in women with sickle cell disease and employer-sponsored insurance.Contraception · 2026Article
- High concordance of physician-attestation with manual data abstraction for sickle cell type: an ASH RC Data Hub study.Blood advances · 2026Article
- Trends in Pregnancy Outcomes in People with Sickle Cell Disease and Medicaid Insurance (2006-2018).Journal of women's health (2002) · 2025Article
- Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.American journal of hematology · 2023Article
- Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception.Blood advances · 2023Article
- Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy.Blood advances · 2023Article
- Common data model for sickle cell disease surveillance: considerations and implications.JAMIA open · 2023Article
- Are children with sickle cell disease at particular risk from the harmful effects of air pollution? Evidence from a large, urban/peri-urban cohort.Pediatric blood & cancer · 2023Article
- Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients.Blood advances · 2023Article
- Pregnancy outcomes in women with sickle cell disease in California.American journal of hematology · 2023Article
- Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia.JAMA network open · 2023Article
- Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018.JAMA network open · 2023Article
- COVID-19 in hospitalized adult patients with sickle cell disease: A 2020 US cohort using Cerner Real-World DataJournal of clinical and translational science · 2023Article
- Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.Journal of clinical medicine · 2022Article
- Use of large scale EHR data to evaluate A1c utilization among sickle cell disease patients.BMC medical informatics and decision making · 2021Article
- Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease.Health science reports · 2021Article
- Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.PloS one · 2021Article
- Machine-learning algorithms for predicting hospital re-admissions in sickle cell disease.British journal of haematology · 2021Article
- Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.Pediatric blood & cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Sickle cell disease affects more than 100,000 individuals in the United States, among whom disease severity varies considerably. One factor that influences disease severity is the sickle cell disease genotype. For this reason, clinical prevention and treatment guidelines tend to differentiate between genotypes. However, previous research suggests caution when using a claimsbased determination of sickle cell disease genotype in healthcare quality studies. The objective of this study was to describe the extent of miscoding for the major sickle cell disease genotypes in hospital discharge data. Individuals with sickle cell disease were identified through newborn screening results or hemoglobinopathy specialty care centers, along with their sickle cell disease genotypes. These genotypes were compared to the diagnosis codes listed in hospital discharge data to assess the accuracy of the hospital codes in determining sickle cell disease genotype. Eighty-three percent (sickle cell anemia), 23% (Hemoglobin SC), and 31% (Hemoglobin Sβ
Indexed as
Identifiers
29202133PMC5709815W2797001717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.